Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680418 | 0.84 | LMNA (0.77) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL25680301 | 0.84 | SMN1; SMN2 (0.79) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL20511012 | 0.82 | LMNA (0.70) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL25680259 | 0.81 | LMNA (0.71) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL20511375 | 0.81 | LMNA (0.70) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL20510895 | 0.81 | LMNA (0.70) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL25680284 | 0.80 | LMNA (0.70) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL20511144 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL25680291 | 0.80 | LMNA (0.69) | LMNASMN1; SMN2L3MBTL1MAPTHPGD | |
| SCHEMBL20511326 | 0.79 | LMNA (0.67) | LMNASMN1; SMN2L3MBTL1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11555031-B2 | Compounds and methods for regulating insulin secretion | THE BROAD INSTITUTE, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3601326-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | The Broad Institute, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175324-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | THE BROAD INSTITUTE, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142508-A1 | COMPOUNDS AND METHODS FOR REGULATING INSULIN SECRETION | IAPP, GPR119, PNLIP | LMNA 4022/4885SMN1; SMN2 4513/4885L3MBTL1 4167/4885 |
| US-11555031-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, INSR | LMNA 3885/4885SMN1; SMN2 4326/4885L3MBTL1 4590/4885 |
| US-12486258-B2 | Compounds and methods for regulating insulin secretion | IAPP, GPR119, PNLIP | LMNA 4022/4885SMN1; SMN2 4513/4885L3MBTL1 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.